The estimated Net Worth of Ronald A Ahrens is at least 422 千$ dollars as of 9 May 2014. Ronald Ahrens owns over 6,000 units of HeartBeam Inc stock worth over 422,165$ and over the last 11 years Ronald sold BEAT stock worth over 0$.
Ronald has made over 2 trades of the HeartBeam Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Ronald bought 6,000 units of BEAT stock worth 44,220$ on 9 May 2014.
The largest trade Ronald's ever made was buying 6,000 units of HeartBeam Inc stock on 9 May 2014 worth over 44,220$. On average, Ronald trades about 2,750 units every 44 days since 2013. As of 9 May 2014 Ronald still owns at least 187,629 units of HeartBeam Inc stock.
You can see the complete history of Ronald Ahrens stock trades at the bottom of the page.
Ronald's mailing address filed with the SEC is 227 Washington St, Conshohocken, PA 19428, USA.
Over the last 11 years, insiders at HeartBeam Inc have traded over 23,124,978$ worth of HeartBeam Inc stock and bought 31,500 units worth 221,145$ . The most active insiders traders include Joseph H Capper、Heather C Getz、Willem Elfrink. On average, HeartBeam Inc executives and independent directors trade stock every 32 days with the average trade being worth of 55,046$. The most recent stock trade was executed by Urioste George De on 6 September 2024, trading 1,674 units of BEAT stock currently worth 3,917$.
heartbeam developed a mhealth technology that is diagnostically equivalent to a cardiologist reading a patient’s 12 lead ecg and examining the patient. it comprises a credit card size, 12 lead equivalent, ecg device and a cloud-based diagnostic expert system. studies designed by harvard medical school faculty have shown heartbeam performance to be equal or better than world class cardiologists in diagnosing a heart attack. the technology features personalized diagnostic thresholds and novel heart attack ecg markers from which the application can also help cardiologists locate a heart attack on a 3d model of the heart. heartbeam's icardiologist application utilizes artificial intelligence / machine learning to drive continuous improvements of the system's ability to provide patient analysis and improve the solution's predictive properties.
HeartBeam Inc executives and other stock owners filed with the SEC include: